Content
Trulieve Cannabis Q4 Net Loss Increased By 32%
Article By:
Lorimer Wilson
Read
Friday, March 8, 2024 1:38 PM EDT
The CEO reports that "Q4 momentum was underpinned by improved consumer trends...[and, given the company's] strong cash generation and a clearly defined strategy, it is well positioned for the coming wave of meaningful growth catalysts."
In this article: TCNNF
Mapping Out America's Cannabis Dispensaries
Article By:
Tyler Durden
Read
Wednesday, March 6, 2024 11:32 PM EDT
American think-tank Pew Research released a new analysis that shows although marijuana is illegal at the federal level, many Americans live in states where cannabis is legal for medical or recreational use.
European Cannabis Q4 2023 Quarterly Update
Article By:
Michael Sassano
Read
Wednesday, March 6, 2024 6:20 PM EDT
Although Europe had a slow year along with most developed markets, the upbeat drums of new countries have invigorated the industry.
Cronos Q4 Financials Are Disappointing: Net Loss Soars By 2725%!
Article By:
Lorimer Wilson
Read
Wednesday, March 6, 2024 4:46 PM EDT
Cronos Q4 were disappointing with revenue down, gross profit down, gross margin down and adjusted EBITDA down as well.
In this article: CRON
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
Article By:
Lorimer Wilson
Read
Monday, February 19, 2024 12:05 AM EDT
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
Article By:
Lorimer Wilson
Read
Sunday, February 18, 2024 6:14 PM EDT
IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the FDA regarding the development of CannQuit-N for tobacco smoking cessation and relapse control.
As Expected, Cannabis MSOs Continue To Decline
Article By:
Lorimer Wilson
Read
Saturday, February 17, 2024 10:01 PM EDT
Last week I suggested that if the performance of the American Cannabis MSO Stocks Index (-7.1%) was any indication, then the hype in cannabis MSOs was over. That is indeed the case, as reflected by the further 6.6% decline this week.
Aurora Cannabis Q3 Financials Unimpressive: Stock Declines
Article By:
Lorimer Wilson
Read
Tuesday, February 13, 2024 4:18 PM EDT
Expects revenue increases, combined with continued cost controls and the acquisition of the remaining 90% of MedReleaf Australia, will be accretive to Adjusted EBITDA and accelerate its efforts to generate positive free cash flow this calendar year.
In this article: ACB